RIFFIT's mission is to empower people to create songs from any text in real time. RIFFIT aims to enhance communication and learning, provide treatment for clinical indications and to entertain, using song. Dyslexia, Autism and Aphasia pose spelling, speaking, reading and comprehension challenges. RIFFIT’s AI enabled real time song provides on-demand access to tools (cutting edge song API and https://app.songr.ai/ , https://app.riffitnow.com/).

Digital Therapeutics

Member Board of Directors at DeuteRx

Lex H.T. Van der Ploeg is Managing Director for VDP, LLC, an independent consulting agency focused on guiding Research and Development for the Biotechnology and Pharmaceutical Industries and private investors. At VDP, LLC, Lex focuses on supporting R&D initiatives from a strategic and tactical perspective, as an integrated part time member of Management and R&D teams.

DeuteRx, LLC is a continuation of Deuteria Pharmaceuticals, Inc.Role: Strategy and R&D

RIFFIT: Development of Digital Therapeutics for the Treatment of Learning Disorders: Visit: RIFFITNOW.com

Member Board of Directors

Rhythm Pharmaceuticals, Inc. formerly known as Rhythm Metabolic, Inc.Motus Therapeutics, Inc. formerly known as Rhythm Pharmaceuticals, Inc.

Strategy and R&D

Head Abraxis Health, R&D, Alliances and DiagnosticsExpand the Abraxis Research Pipeline and develop personalized patient management infrastructures. Matured and established CLIA laboratories, one with CAP accreditation; developed and marketed LDTs for Cervical cancer, Melanoma and Colorectcal Cancer. Develop platform technologies for high content patient data capture. Mature therapeutics and companion diagnostics. Chairman of the Board Shimoda Biotech and Platco TechnologiesMember Board of Directors DiTheraMember Board of Directors Expression Pathology, IncMember Board of Directors NeoDiagnostixMember Board of Directors Metabit, LLCMember Board of Directors Abraxis BioSensors, LLCMember Board of Directors Cenomed Inc

Assistant Professor 1984; Tenured Associate Professor, 1987; Adjunct Associate Professor, 1992-2009, Department of Genetics and Development

From Dec 2003 through Dec 2008 opened and established Merck's research site in the Boston Longwood medical area focused on drug discovery for the treatment of cancer and Alzheimer's disease. Prior to this functioned as Vice President and Site head of Merck San Diego (2003), and from 1996-2002 as Sr Director and Executive Director Metabolism-Obesity Research at Merck's Rahway, NJ and Japan, Banyu research facilities.

Site head Merck San Diego. Focus on Stroke and Neurodegenerative Diseases

Head Obesity Research Rahway, NJ - Banyu, Japan

Elucidate Mechanisms of action Growth Hormone Secretagogues-discovered new neuroendocrine pathway for Growth Hormone release, later shown by others, to be controlled by the hormone ghrelinEstablish Merck's transgenic rodent facility and infrastructureEstablish Merck's drosophila genetics teamSupport Animal Health efforts

Elucidate Mechanism of action growth hormone secretagoguesElucidate Mechanism of action AvermectinBuild transgenic models for neurodegenerative disease